Biocon announced the appointment of Shreehas Tambe as Chief Executive Officer (CEO) and Managing Director, effective April 1, 2026. Tambe, an internal veteran with nearly three decades at Biocon (previously CEO & MD of Biocon Biologics, where he led biosimilars growth to a USD 5.5 billion valuation in 2025 and handled key acquisitions/operations), will lead the unified entity post full integration of Biocon Biologics as a wholly owned subsidiary. Concurrently, Kedar Upadhye was appointed Chief Financial Officer (CFO) of Biocon Limited. Siddharth Mittal (prior CEO & MD and long-time CFO since 2013) is transitioning to another leadership role within the Biocon Group. The changes were approved by the Nomination & Remuneration Committee and Board.054.